Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 0.75 |
| ▸ | JAK2 | O60674 | 4/20 | 0.75 |
| ▸ | LCK | P06239 | 3/20 | 0.75 |
| ▸ | JAK1 | P23458 | 2/20 | 0.75 |
| ▸ | TYK2 | P29597 | 2/20 | 0.75 |
| ▸ | STAT3 | P40763 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909912 | 1.00 | JAK3 (0.75) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL9101101 | 0.94 | JAK3 (0.76) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL10207518 | 0.89 | JAK3 (0.80) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL21538587 | 0.89 | JAK3 (0.80) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL21538584 | 0.88 | JAK3 (0.79) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL23717341 | 0.88 | JAK3 (0.77) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL12546710 | 0.87 | JAK3 (0.85) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL26453160 | 0.87 | JAK3 (0.85) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL1948607 | 0.87 | JAK3 (0.71) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL19011863 | 0.86 | JAK3 (0.76) | JAK3JAK2LCKJAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321271-B1 | METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | JAPAN TOBACCO INC (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-11339181-B2 | Crystalline forms of a Janus kinase inhibitor | JAPAN TOBACCO INC. (JP) | 2022-05-24 | — | — | US | disclosed |
| US-10822354-B2 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof | JAPAN TOBACCO INC. (JP) | 2020-11-03 | — | — | US | disclosed |
| EP-3559003-A1 | CRYSTALLINE FORMS OF A JANUS KINASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018117153-A1 | CRYSTALLINE FORMS OF A JANUS KINASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2018-06-28 | — | — | WO | disclosed |
| EP-3321271-A1 | METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | Japan Tobacco, Inc. (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339181-B2 | Crystalline forms of a Janus kinase inhibitor | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885LCK 99/4885 |
| US-10822354-B2 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885LCK 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.